Investor Overview

Synta Overview
Synta Pharmaceuticals is an innovative, agile biopharmaceutical company focused on research, development and commercialization of novel oncology medicines that have the potential to change the lives of cancer patients. ... More >>
Recent NewsMore >>
06/23/15Synta Announces Journal Publication Describing Complementary Activity of Hsp90 Inhibition and Immune Checkpoint Blockade for Cancer Therapy
LEXINGTON, Mass.--(BUSINESS WIRE)--Jun. 23, 2015-- Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced the publication in this month’s issue of Cancer Immunology Research of an in-depth review describing the rationale for pursuing the combination of Hsp90 and immune checkpoint inhibition for cancer therapy. The review article, titled “Targeting Heat-Shock Protein 90 (Hsp90) as a Complementary Strategy to Immune Checkpoint Blockade for Cance... 
Printer Friendly Version
06/16/15Synta to Participate in Upcoming Investor Conferences
- Presenting at JMP Securities Life Sciences Conference 2015 - - Participating in 2nd Annual ROTH Healthcare Corporate Access Day - LEXINGTON, Mass.--(BUSINESS WIRE)--Jun. 16, 2015-- Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced that the Company will present at the JMP Securities Life Sciences Conference 2015 on Tuesday, June 23rd at 12:30 p.m. (ET) in New York. A live audio webcast and replay of the presentation w... 
Printer Friendly Version
06/02/15Synta Announces Ganetespib Program Updates
First Patient Enrolled in Phase 2 Portion of GANNET53 Study of Ganetespib in Ovarian Cancer Phase 2 GALAXY-1 Trial of Ganetespib in NSCLC Published in Annals of Oncology LEXINGTON, Mass.--(BUSINESS WIRE)--Jun. 2, 2015-- Synta Pharmaceuticals Corp. (NASDAQ:SNTA) today announced updates to its clinical program for Ganetespib, a next-generation inhibitor of the chaperone protein Hsp90. Ganetespib is currently being studied in sever... 
Printer Friendly Version
05/28/15Synta Announces Presentations at the 2015 ASCO Annual Meeting
Feasibility of Ganetespib Combination Therapy Demonstrated in Three Investigator-Sponsored Trials STA-12-8666 Results in Pediatric Sarcoma Models Highlighted in Poster Discussion Session LEXINGTON, Mass.--(BUSINESS WIRE)--May 28, 2015-- Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced that Phase 1 clinical results from three investigator-sponsored trials evaluating ganetespib combination therapy in ALK-positive lung cancer, ... 
Printer Friendly Version

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.
Stock Quote
SNTA (Common)
ExchangeNASDAQ (US Dollar)
Change (%) Stock is Down 0.02 (0.91%)
Data as of 07/02/15 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Synta 2014 Form 10-K